Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
78-week open-label extension study of BI 1356 (linagliptin) in type 2 diabetes mellitus
2008-000750-13Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Primary endpoint: Safety and tolerability (long-term). Started May 2008; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-000750-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000750-13.